SBRT2015

Hypofractionated, Conventional delivery

• Phase NCIC CTG BR.25 II study • 80 biopsy-proven, peripherally located, T1-3 N0 M0 NSCLC • (2006 to 2008, 17 Canadian institutions) • 60 Gy in 15 fractions, using 3DCRT . No inhomogeneity correction or IMRT use, with fluoroscopy for motion evaluation • GTV= primary tumor only; PTV margin = 1.0 to 1.5 cm. • Primary endpoint: 2-year primary tumor control rate.

Cheung PC, JNCI 2014